Ceritinib Linked With Greater Overall, Progression-free Survival for Patients With NSCLC
Ceritinib may prolong overall survival (OS) and progression-free survival (PFS), in contrast with crizotinib in ALK+ non-small cell lung cancer.
Ceritinib may prolong overall survival (OS) and progression-free survival (PFS), in contrast with crizotinib, when used as initial anaplastic lymphoma kinase (ALK)-targeted therapy for patients with previously treated ALK+ non-small cell lung cancer (NSCLC), according to a study published in the Journal of Thoracic Oncology.1
Researchers led by Daniel Shao-Weng Tan, MD, of the National Cancer Centre, Singapore, collected data from 198 patients treated with ceritinib and 557 who were treated with crizotinib, as part of 2 single-arm ASCEND-1 and ASCEND-3 trials.
Average baseline characteristics were matched using propensity score weighting to adjust for cross-trial differences.
RELATED: Minocycline May Improve Treatment-related Fatigue in Patients With NSCLC
It was found that ceritinib was associated with longer OS and PFS, in contrast with crizotinib, upon Cox proportional hazards models. Twelve-month OS was found to be 82.6% with ceritinib and 66% with crizotinib upon Kaplan-Meier analysis.
No significant differences were found in overall response rates between the 2 groups.
- Tan DS, Araujo A, Zhang J, Signorovitch J, Zhou ZY, Cai X, et al. Comparative Efficacy of Ceritinib and Crizotinib as Initial Anaplastic Lymphoma Kinase-targeted Therapies in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: an Adjusted Comparison to External Controls. [published online ahead of print June 8, 2016.] J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.05.029